Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(79 products)
- Syk(37 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1420 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TX2-121-1
CAS:<p>TX2-121-1 targets HER3 for proteasome-mediated degradation to inhibit HER3-dependent signalling and growth.</p>Formula:C42H52N8O3Purity:98%Color and Shape:SolidMolecular weight:716.91ALK-IN-23
<p>ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.</p>Formula:C26H29ClN8O3SColor and Shape:SolidMolecular weight:569.08EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formula:C27H31ClN7O3PColor and Shape:SolidMolecular weight:568.01FGFR4-IN-9
<p>FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.</p>Formula:C24H22ClF3N4O4Color and Shape:SolidMolecular weight:522.9BTK-IN-10
CAS:<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Formula:C25H24F2N4O2Color and Shape:SolidMolecular weight:450.48(-)-Cevimeline hydrochloride hemihydrate
<p>(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.</p>Formula:C10H19ClNO1·5SPurity:98%Color and Shape:SolidMolecular weight:244.78Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63MTX-216
CAS:<p>MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.</p>Formula:C22H14Cl2FN5O2SColor and Shape:SolidMolecular weight:502.348FGFR4-IN-6
<p>FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.</p>Formula:C31H33N7O4Color and Shape:SolidMolecular weight:567.64CEP-14083
CAS:<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Formula:C31H30N6O2Color and Shape:SolidMolecular weight:518.61BTK inhibitor 18
<p>BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.</p>Formula:C29H25N5O4S2Color and Shape:SolidMolecular weight:571.67EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Formula:C18H21N5O3SColor and Shape:SolidMolecular weight:387.46JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Formula:C30H32N6O4Color and Shape:SolidMolecular weight:540.61JNJ-47117096
CAS:<p>JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.</p>Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.425EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98FAK inhibitor 6
CAS:<p>Compound 26F: potent enzyme inhibitor (IC50=28.2nM), low cytotoxicity (IC50=3.32μM), induces dose-dependent apoptosis in MDA-MB-231, blocks G0/G1 phase.</p>Formula:C25H24FN5O2SColor and Shape:SolidMolecular weight:477.55
